Drugs / BAY2416964
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04999202 | Aug 2021 → Jun 2024 | cancer | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT04069026 | Aug 2019 → Jan 2024 | cancer | Bayer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Bayer | Results Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting bayer.com ↗
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Bayer | Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting bayer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2416964 | “Six dose levels of BAY 2416964 (as determined in the first in human mono-therapy study of BAY2416964) are planned in combination with standard dose Pembrolizumab.” NCT04999202 ↗ |
| Action | Inhibit | “blocks the Aryl Hydrocarbon Receptor” NCT04069026 ↗ |
| Modality | Small molecule | “BAY2416964 is a small molecule” NCT04069026 ↗ |
| Route | Oral | “Oral application of study drug daily in a predefined dose escalation scheme.” NCT04069026 ↗ |